Presentationer

Läs mer:

Pressmeddelanden
Finansiella rapporter
Kalender
Presentationer
Aktien
Bolagsstyrning
Prenumerera

Pressmeddelanden
Finansiella rapporter
Kalender
Presentationer
Aktien
Bolagsstyrning
Prenumerera

Kategorier

Arkiv per år

2022
2021
2020
2019
2018
2017
2016
2015

RSS

Hämta RSS-flöde

CEO Andreas Bhagwani presents Nanologica’s Interim Report Q3 2022

11 November, 2022

Nanologicas vd Andreas Bhagwani presenterar med anledning av pågående företrädesemission

20 September, 2022

Den 27 september 2022, kl 12.00 bjuder Nanologica in till en presentation och frågestund med Nanologicas vd Andreas Bhagwani hos Infront Direkt Studios, Kungsgatan 33, 115 56 Stockholm. Anmälan sker till ir@nanologica.com. Presentationen kommer även att sändas live via länk:

Nanologica AB presenterar på Erik Penser Banks bolagsdag 24 augusti

23 August, 2022

Vd Andreas Bhagwani presenterar Nanologica den 24 augusti kl 13.05 på Erik Penser Banks bolagsdag.

Kommentar från vd Andreas Bhagwani gällande företrädesemission

23 August, 2022

Vd Andreas Bhagwani kommenterar Nanologicas företrädesemission om upp till 94 MSEK som annonserades den 23 aug 2022. Företrädesemissionen görs i syfte att kunna intensifiera bolagets satsningar inom preparativ kromatografi.

CEO Andreas Bhagwani presenting At Naventus Healthcare Summit May 10, 2022

11 May, 2022

Vd Andreas Bhagwani presenterar första kvartalet

29 April, 2022

« Previous Next »

Nanologica AB (publ)
Forskargatan 20 G
SE-151 36 Södertälje
Sweden

Email: info@nanologica.com
Tel: +46 (0)8 410 749 49

To subscribe to our press releases and financial reports, please enter your e-mail address:

Acceptance

Yes, I want to subscribe.

About us

Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products.

The company’s vision is to contribute to better and cheaper medicine through porous silica. In Chromatography, the aim is to make diabetes drugs and other peptide-based drugs available to more patients by providing products that can lower the production costs at the manufacturers. In Drug Development, the company’s platform for inhalation is developed to give patients with severe lung diseases access to new or improved treatments.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings ACCEPT

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT